Bradenton, FL (PRWEB) – Gould & Lamb and myMatrixx® announced that they have entered into an agreement to provide an enhanced program combining myMatrixx’s comprehensive clinical oversight and drug regimen reviews for insurance carriers, third party administrators and self-insured entities called Stop the Pain. The new program will identify individuals who are high risk for potential abuse and misuse of medications using predictive modeling including historical data and evidence-based medicine.
The program will include complete drug utilization review by pharmacists, targeted communications with physicians and drug treatment management. By addressing the clinical appropriateness of prescribed drugs and reviewing alternative treatment plans, avoidable medical expenses can be prevented. The end goal is lower costs of care and improved outcomes for the individuals in the program.
Deborah Pfeifle, President of Gould & Lamb commented, “As the use of narcotics and pharmacy costs have soared to unprecedented levels, insurance adjusters and employers are seeking clinical advice and medication management. We are very excited to partner with myMatrixx who is a leader in this area and has developed proven clinical programs designed with cost savings and patient care in mind.”
Phil Walls R.Ph., Chief Clinical and Compliance Officer with myMatrixx added, “We are excited about the opportunity to work with Gould & Lamb in an area that both companies are very passionate about. Our ability to deliver a clinically focused solution will continue to lead the industry in solving the medication management challenges of today and the future.”